Evidence has suggested that the combination of KRAS and EGFR mutation may have a negative impact on the efficacy of TKI treatment,41 but EGFR‐TKI may be an effective choice for the treatment of patients with NSCLC with comutation of EGFR/KRAS.44 This evidence concerns the gene KRAS and non-small cell lung carcinoma.